Evidence map›Paper›PMID 33889306›Full record

ArticleOncotarget2021

High

Elodie Montaudon, Rania El Botty, Sophie Vacher, Olivier Déas, Adnan Naguez, Sophie Chateau-Joubert, Damien Treguer, Ludmilla de Plater, Leïla Zemoura, Fariba Némati and 12 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Frontiers in oncology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 1 country.

Elodie MontaudonLaboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France.
Rania El BottyLaboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France.
Sophie VacherDepartment of Genetics, Institut Curie, Paris, France.
Olivier DéasXentech, Evry, France.
Adnan NaguezLaboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France.
Sophie Chateau-JoubertBioPôle Alfort, National Veterinary School of Alfort, Maisons Alfort, France.
Damien TreguerLaboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France.
Ludmilla de PlaterLaboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France.
Leïla ZemouraDepartment of Pathology, Hôpital Foch, Suresnes, France.
Fariba NématiLaboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France.
André NicolasDepartment of Tumor Biology, Institut Curie, Paris, France.
Alain ChapelierDepartment of Thoracic Surgery, Hôpital Foch, Suresnes, France.
Alain LivartowskiInstitut du Thorax Curie Montsouris, Institut Curie, Paris, France.
Stefano CairoXentech, Evry, France.
Catherine DanielInstitut du Thorax Curie Montsouris, Institut Curie, Paris, France.
Marie BrevetCYPATH, Centre Léon Bérard, Lyon, France.
Elisabetta MarangoniLaboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France.
Didier MeseureDepartment of Tumor Biology, Institut Curie, Paris, France.
Sergio Roman-RomanDepartment of Translational Research, Institut Curie, PSL University, Paris, France.
Ivan BiecheDepartment of Genetics, Institut Curie, Paris, France.
Nicolas GirardInstitut du Thorax Curie Montsouris, Institut Curie, Paris, France.
Didier DecaudinLaboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France.
Institut Curie · FRUniversité Paris Sciences et Lettres · FRHôpital Foch · FRCentre Léon Bérard · FRÉcole Nationale Vétérinaire d'Alfort · FRInstitut du Thorax · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Significant rational is available for specific targeting of PI3K/AKT/mTOR pathway in the treatment of non-small cell lung cancer (NSCLC). However, almost all clinical trials that have evaluated Pi3K pathway-based monotherapies/combinations did not observe an improvement of patient's outcome. The aim of our study was therefore to define combination of treatment based on the determination of predictive markers of resistance to the mTORC1 inhibitor RAD001/Everolimus. An

Indexed as

mTORC1NSCLCPi3K signalling pathwayPLK1RAD001 (everolimus)

Identifiers

PMID33889306
PMCPMC8057272
OpenAlexW3153785355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.